0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 04:40 ET (09:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。